Adalimumab Biosimilar Transition Studies Reported at ECCO’21 Congress – The Center for Biosimilars
Presentations at the European Crohn’s and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data. CONTEXT: Among the poster presentations described in this article Continue Reading
